The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma

Background CA19-9 is a tumor marker for pancreatic cancer, cholangiocarcinoma, and other malignancies. However, its sensitivity and specificity is suboptimal in clinical practice, which we hypothesized limits its clinical utility. Aims To evaluate the clinical utility and limitations of CA19-9 as a...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2011-08, Vol.56 (8), p.2491-2496
Main Authors: Singh, Sundeep, Tang, Shou-jiang, Sreenarasimhaiah, Jayaprakash, Lara, Luis F., Siddiqui, Ali
Format: Article
Language:English
Subjects:
Adenoma - diagnosis
Antigens
Bile Duct Neoplasms - blood
Bile Duct Neoplasms - diagnosis
Bile Ducts, Intrahepatic
Biochemistry
Biological and medical sciences
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
Cancer
Cholangiocarcinoma - blood
Cholangiocarcinoma - diagnosis
Choledocholithiasis - blood
Choledocholithiasis - diagnosis
Cholestasis - blood
Cholestasis - diagnosis
Comparative analysis
Feeding. Feeding behavior
Female
Fundamental and applied biological sciences. Psychology
Gastroenterology
Gastroenterology. Liver. Pancreas. Abdomen
Hepatology
Hospitals
Humans
Jaundice - blood
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Medicine
Medicine & Public Health
Oncology
Oncology, Experimental
Original Article
Pancreatic cancer
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - diagnosis
Retrospective Studies
ROC Curve
Sensitivity and Specificity
Transplant Surgery
Tumors
Vertebrates: anatomy and physiology, studies on body, several organs or systems
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background CA19-9 is a tumor marker for pancreatic cancer, cholangiocarcinoma, and other malignancies. However, its sensitivity and specificity is suboptimal in clinical practice, which we hypothesized limits its clinical utility. Aims To evaluate the clinical utility and limitations of CA19-9 as a tumor marker. Methods We performed a retrospective review of CA19-9 levels (U/ml) in 483 consecutive patients between 2006 and 2008 at two university hospitals. We abstracted clinical, radiographic, and pathological data and final diagnoses. Descriptive and non-parametric analyses were performed. Results Patients presenting with jaundice had the highest CA19-9 (420) compared to other complaints (
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-011-1709-8